Tevogen Regains Compliance with Nasdaq Global Market Continued Listing Requirements
Nasdaq confirmed compliance with the $50 million minimum market value of listed securities requirement.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Tevogen (Nasdaq: TVGN) has regained compliance with Nasdaq Global Market continued listing requirements, closing both previously disclosed compliance matters.
Nasdaq's written notice received September 29, 2026, confirmed compliance with the $50 million minimum market value of listed securities requirement under Listing Rule 5450(B)(2)(A). A separate notice received September 9, 2026, confirmed compliance with the minimum market value of publicly held shares requirement under Rules 5450(B)(2)(C) and 5450(B)(3)(C). Both requirements are now satisfied.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointCompliance restored with Nasdaq's $50 million minimum market value of listed securities requirement; related matter closed.
- Moderate pointMinimum market value of publicly held shares compliance restored; related Nasdaq matter also closed.
Negative
- None.
Key Figures
- Minimum market value threshold
- $50 million
- Nasdaq continued listing requirement; compliance regained
AI-generated analysis. How Rhea-AI works. Not financial advice.
Both previously disclosed Nasdaq compliance matters are now closed
WARREN, N.J., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Tevogen Inc. (“Tevogen” or the “Company”) (Nasdaq: TVGN), an integrated healthcare enterprise combining biotechnology, artificial intelligence, and healthcare services to improve the affordability and accessibility of life-saving medicines, today announced that it received written notice from The Nasdaq Stock Market LLC (“Nasdaq”)on September 29, 2026, confirming that the Company had regained compliance with the
As previously announced, on September 9, 2026, the Company had received written notice from Nasdaq confirming that it had regained compliance with the minimum market value of publicly held shares requirement under Nasdaq Listing Rules 5450(B)(2)(C) and 5450(B)(3)(C).
With both requirements satisfied, the related Nasdaq compliance matters are now closed.
About Tevogen
Tevogen is a healthcare enterprise focused on improving the affordability and accessibility of life-saving medicines. The Company brings together three complementary efforts: Tevogen Bio, its biotechnology initiative; Tevogen.AI, its artificial intelligence and technology initiative; and Tevogen Healthcare Services, its emerging healthcare services initiative.
Together, these efforts are designed to create a more integrated healthcare model in which science, technology, and operational efficiency work together to reduce the cost of medication and expand patient access.
Contacts
Tevogen Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Has Tevogen regained compliance with Nasdaq continued listing requirements?
Both previously disclosed Nasdaq compliance matters are now closed. Tevogen satisfied the minimum market value of listed securities requirement and the minimum market value of publicly held shares requirement.
When did Nasdaq confirm Tevogen's restored compliance?
Tevogen received written confirmation on September 29, 2026, for the $50 million minimum market value of listed securities requirement. It received the earlier confirmation for the minimum market value of publicly held shares requirement on September 9, 2026.